Sangamo Therapeutics

Historical price data

Sangamo Therapeutics is a genomic medicine company with a mission to develop lasting, potentially curative therapies for severe diseases using its foundational zinc finger protein (ZFP) technology. The company has achieved clinical proof-of-concept across multiple modalities, most notably with its lead gene therapy candidate, isaralgagene civaparvovec (ST-920), for Fabry disease, for which it is preparing a Biologics License Application (BLA) submission. Its strategy combines advancing a wholly-owned neurology pipeline with leveraging its platform through strategic collaborations with major pharmaceutical firms like Pfizer, Novartis, Takeda, and Lilly to expand into other therapeutic areas and share development costs.

Proprietary Zinc Finger Protein (ZFP) platform enabling precise DNA targeting for gene editing, epigenetic repression, and regulation, distinguished by its high specificity, compact size for AAV delivery, and human-derived protein origin.